Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. - Wikidata - awgldk - TriplyDB

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

http://www.wikidata.org/entity/Q44089673

about

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update Hepatocellular carcinoma in elderly patients: challenges and solutions Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments Dietary Natural Products for Prevention and Treatment of Liver Cancer Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review Interventions for preventing or treating malnutrition in problem drinkers who are homeless or vulnerably housed: protocol for a systematic review Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments Management of hepatocellular carcinoma with portal vein thrombosis Drug therapy for advanced-stage liver cancer Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement Hepatocellular carcinoma: a review First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives Hepatocellular carcinoma: A comprehensive review Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.Comparison of hepatocellular carcinoma in Eastern versus Western populations.Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.Multidisciplinary management of hepatocellular carcinoma in clinical practice.Reassessing hepatocellular carcinoma staging in a changing patient population.Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.Radioembolization of hepatic tumors Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.Association of Notch1 with vasculogenic mimicry in human hepatocellular carcinoma cell lines An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.New progress of non-surgical treatments for hepatocellular carcinoma.Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.

P2860

Q24619987-92248ED3-67E4-4527-8273-E1F86E476E90 Q26738274-3CFF8509-AE67-48FF-9049-4F7A94958C71 Q26738533-C491C8A8-527F-47C7-8DD7-7376AD7D3602 Q26743603-31F9D3BB-CCB0-44A1-845A-DC6D0269B367 Q26743666-8DC3CDD4-5176-4DDA-8556-1558E48F30BA Q26765440-BAAE89FB-65AC-4AB3-BC05-89B0EC464EB5 Q26766707-64536CBD-459E-4778-A4CA-6F65823F05CA Q26772299-C81564A0-A328-4A49-AE28-CA5CBFEBD9EF Q26783730-4D20B1D9-200F-48A4-B8C4-9AF7CB8942E2 Q26784223-C57414D9-9371-41AF-917B-E3EF9E9C6E7F Q26851033-7BF66D20-0313-4983-8A86-9755534DEE8A Q26852174-36ACBAF5-4DB0-4754-973A-6C85E8F221BD Q26996578-63958FCB-3D41-45B5-AA9D-575C64745FD8 Q27004410-2674DEF9-7B73-4F56-8F58-3571E24D67EE Q27022015-0CF72B90-C4A2-4A7D-99A8-1C053AD1F209 Q27026858-C2FA30C9-34CF-40B8-BA04-1CA5F99D0DC0 Q28066038-30CC5B98-D884-42A1-9D06-088485A9F93C Q28069290-BE1D35F1-8686-402D-ADCD-22D61E0141F9 Q28073654-A18A56E7-592B-49A1-861C-24C621992AAA Q28077829-92378F08-E52F-4184-81E3-1D572543AAFA Q28079378-52B89322-DCD4-4107-9780-F508BD68A92C Q28081783-54B74FDB-248E-47FC-96EC-018A67002657 Q28087638-BA3FC47E-13B2-4D91-802C-8E67514A005D Q30240748-EB4916F7-1354-4F22-9A37-44F0244AA0E5 Q30245396-C845DFAB-8310-4546-9288-E09E192F2C9F Q30248206-77673231-8DE9-4830-8EFB-4CBF039AB469 Q32177411-289099A1-EA4F-43C5-81B1-E45F4F7C434A Q33429082-CDB60E3D-A60B-4A4A-878B-540D823A401B Q33627217-7D53F965-C793-40F8-97BC-B3A37FC044B6 Q33666679-603EA941-12C9-493C-A53A-CDB53F3F19B2 Q33767286-42B614F9-3C14-4E73-A413-C31BD4841638 Q33797067-E00C3B86-E9EA-4181-9476-8C18F553E466 Q33807832-BDB0ABAC-9615-47A1-999F-1B885645DF68 Q33820777-09D6886B-AD57-4C59-838E-1B4B3488C57B Q33948042-E5A4A8A6-EFC9-452A-96CE-8FD1A8E735CE Q34371351-6275B597-3195-47A1-94D2-E7217CC4F776 Q34611731-CDC3A030-9B40-4655-9004-FC07300DC633 Q34647076-52533747-CA9A-4045-B3AF-F51E22DA14A8 Q34786090-108B51CA-7CE6-4C5D-9372-9D4824F6E97F Q35025403-A2104D84-49F7-40E8-8302-D5F5ADE0B57C

P2860

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

http://www.wikidata.org/entity/Q44089673

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Efficacy and safety of sorafen ...... analyses of a phase III trial.

@en

Efficacy and safety of sorafen ...... analyses of a phase III trial.

@nl

type

label

Efficacy and safety of sorafen ...... analyses of a phase III trial.

@en

Efficacy and safety of sorafen ...... analyses of a phase III trial.

@nl

prefLabel

Efficacy and safety of sorafen ...... analyses of a phase III trial.

@en

Efficacy and safety of sorafen ...... analyses of a phase III trial.

@nl

P1433

Q44089673-54210CA6-E3A8-4E00-AAB9-BD2A56C10A2C

P1476

Q44089673-72EBC91C-BD28-4DD5-B32C-95A473220A74

P2093

Q44089673-0753D86C-342E-4BA0-BC97-B3479F4180DB

Q44089673-0E539370-4C68-4098-87CA-FBE6A0D5F83A

Q44089673-468B7AD6-38F5-4BBF-8638-82E8CA8871AA

Q44089673-651C7193-CB32-48A3-9DEA-26621F0D05E7

Q44089673-71161057-3F68-4BCB-8CEE-E4C170C169C3

Q44089673-7C0593A7-3D19-434C-9BB1-C4A0129AAAB6

Q44089673-8A7BD509-16C2-4AD5-BC4C-115C7FC13B9D

Q44089673-8B0B3E04-AAEF-4855-A931-28782E7FFA62

Q44089673-8D24CF9C-669D-4B97-B31B-EDD585751360

Q44089673-CD84861F-9CD9-4ECD-9460-56E470D05E38

P304

Q44089673-3B11C25A-9320-400E-8A4A-974B3C1FA544

P31

Q44089673-7021B43D-BE48-4FF4-A584-D783FA49FD7C

P356

Q44089673-0B76E5F5-BC8D-4C26-B966-C9AB7DDC26CF

P433

Q44089673-A76CF8D1-9A50-4E3F-AC38-FC0803D54F7C

P478

Q44089673-55F983E4-0743-4B0E-BCE2-6BEEBFD6F5F3

P50

Q44089673-0B8D4ED1-B278-42F4-90B8-16CF1C86CE35

Q44089673-2BBA320E-F4D1-49F8-9F5E-6CE45A3CE162

Q44089673-6BE9D253-3259-4D07-AC7C-A4BB78B10AE6

Q44089673-A25E48D2-B708-4C35-81CF-D68FB269BAF8

Q44089673-E6017F01-299E-494A-B62B-B8B7E24B76E5

P577

Q44089673-0684977B-037F-490E-B497-EB12E6C639DA

P5875

Q44089673-B762B335-2C33-4992-A94B-94258C2F001A

P698

Q44089673-541BB890-9CD6-4016-9663-3734A17046BC

P921

Q44089673-13E80504-933C-45F0-8DF2-80584A9049D1

Q44089673-87B28F61-50C9-4768-9B18-C9BC417122A5

P356

J.JHEP.2012.06.014

P1433

Journal of Hepatology

P1476

Efficacy and safety of sorafen ...... analyses of a phase III trial.

@en

P2093

Andrea Nadel

http://www.w3.org/2001/XMLSchema#string

Angelo Sangiovanni

http://www.w3.org/2001/XMLSchema#string

Armando Santoro

http://www.w3.org/2001/XMLSchema#string

Dimitris Voliotis

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Raoul

http://www.w3.org/2001/XMLSchema#string

Jorge A Marrero

http://www.w3.org/2001/XMLSchema#string

Luigi Bolondi

http://www.w3.org/2001/XMLSchema#string

Marius Moscovici

http://www.w3.org/2001/XMLSchema#string

Michael Shan

http://www.w3.org/2001/XMLSchema#string

Michel Beaugrand

http://www.w3.org/2001/XMLSchema#string

P304

821-829

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2012.06.014

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Josep M. Llovet

P577

2012-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228061800

http://www.w3.org/2001/XMLSchema#string

P698

22727733

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial